Minireviews
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Apr 21, 2023; 29(15): 2261-2271
Published online Apr 21, 2023. doi: 10.3748/wjg.v29.i15.2261
Immunotherapy for recurrent hepatocellular carcinoma
Ahan Bhatt, Jennifer Wu
Ahan Bhatt, Jennifer Wu, Division of Hematology and Oncology, Perlmutter Cancer Center of NYU Langone Health, NYU School of Medicine, New York, NY 10016, United States
Author contributions: Bhatt A drafted the manuscript, coordinated all the authors’ efforts and provided the final revisions; Wu J provided the concept of the manuscript, established the structure of the manuscript and revised the drafts.
Conflict-of-interest statement: All authors report having no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jennifer Wu, MD, Associate Professor, Attending Doctor, Division of Hematology and Oncology, Perlmutter Cancer Center of NYU Langone Health, NYU School of Medicine, 462 First Ave, BCD556, New York, NY 10016, United States. jennifer.wu@nyulangone.org
Received: September 15, 2022
Peer-review started: September 15, 2022
First decision: January 3, 2023
Revised: January 25, 2023
Accepted: March 14, 2023
Article in press: March 14, 2023
Published online: April 21, 2023
Processing time: 210 Days and 18.8 Hours
Core Tip

Core Tip: Immunotherapy (IO) has made strong headway in the management of hepatocellular carcinoma (HCC). For patients who recur on local therapy, IO has become the standard of care treatment option for unresectable HCC. The role of IO agents is still not explored in patients who progress on prior IO. This mini-review highlighted the various treatment options available in clinical practice as well as upcoming novel management strategies in recurrent HCC.